Adverse event (AE) reporting of oral clodronate with emphasis on osteonecrosis of the jaw.

被引：0
|
作者：
Jones, GR
Lehtinen, T
Riphagen, FE
von Roemeling, R
机构：
[1] Berlex Labs Inc, Seattle, WA USA
[2] Schering Oy, Turku, Finland
[3] Schering Oy, Helsinki, Finland
[4] Schering AG, Montville, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：77S / 77S
页数：1
相关论文
共 50 条
  • [1] Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma
    Montazerit, Amir H.
    Erskine, J. Gordon
    McQuaker, I. Grant
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (01) : 69 - 71
  • [2] Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)
    Zhang, Xiaoyan
    Hamadeh, Issam S.
    Song, Shuang
    Katz, Joseph
    Moreb, Jan S.
    Langaee, Taimour Y.
    Lesko, Lawrence J.
    Gong, Yan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (02) : 336 - 340
  • [3] A DISPROPORTIONALITY ANALYSIS OF SPONTANEOUS ADVERSE EVENT REPORTS FOR OSTEONECROSIS OF JAW ATTRIBUTED TO AROMATASE INHIBITORS IN FDA ADVERSE EVENTS REPORTING SYSTEM
    Reddy, Ravindra N.
    Viswam, S. K.
    Thomas, B. E.
    Bellapu, A.
    Sharma, V
    Chacko, S.
    VALUE IN HEALTH, 2019, 22 : S613 - S613
  • [4] Time to onset analysis of letrozole associated osteonecrosis of jaw in FDA adverse event reporting system (FAERS) database
    Viswam, Subeesh Kulangara
    Reddy, Neha
    Gouri, Nair
    Sai, Minnikanti Satya
    Kunnavil, Radhika
    Maheswari, Eswaran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 460 - 460
  • [5] Bisphosphonate use and osteonecrosis of the jaw: Pharmacovigilance and reporting of this serious adverse event from the Research on Adverse Drug Events and Reports (RADAR) project
    Edwards, B. J.
    Gounder, M.
    McKoy, J.
    Raisch, D.
    Farrugia, M.
    Cesar, M.
    Marx, R.
    Ruggiero, S.
    Dimopoulos, M.
    Bennett, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] BISPHOSPHONATES AND OSTEONECROSIS: ANALYSIS OF THE KOREA ADVERSE EVENT REPORTING SYSTEM
    Kim, N. H.
    Je, S.
    Song, S. M.
    Shin, A. N.
    Suh, D.
    VALUE IN HEALTH, 2017, 20 (05) : A140 - A140
  • [7] Osteonecrosis of the Jaw Associated With Bevacizumab in Treatment: A Case Series Using the FDA Adverse Event Reporting System (FAERS) Database
    Ahdi, Hardeep S.
    Wichelmann, Thomas A.
    Pandravada, Sasirekha
    Ehrenpreis, Eli
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S119 - S119
  • [8] Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)
    Ahdi, Hardeep S.
    Wichelmann, Thomas Adam
    Pandravada, Sasirekha
    Ehrenpreis, Eli D.
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [9] Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)
    Hardeep S. Ahdi
    Thomas Adam Wichelmann
    Sasirekha Pandravada
    Eli D. Ehrenpreis
    BMC Pharmacology and Toxicology, 24
  • [10] Evaluation of Spontaneous Adverse Event Reports for Osteonecrosis of the Jaw (ONJ) Attributed to Denosumab and Zoledronic Acid Within the FDA Adverse Events Reporting System (FAERS)
    Mekkawy, Mohamed A.
    El-Fass, Kareem
    Mohammad, Reem Nagib
    Abou-Ali, Adel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 395 - 396
12345